GONGWIN 6617

6617 TPEX
6617
GONGWIN TPEX
 
No trades
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E

6617 Chart

Trade 6617 with trusted brokers on TradingView Open account
Valuation
Enterprise Value/EBITDA, TTM
Enterprise Value, FQ
Market Cap — Basic
Number of Employees
Number of Shareholders
Price/Earnings, TTM
Price/Revenue, TTM
Price/Book Ratio, FY
Price/Sales Ratio, FY
Balance Sheet
Current Ratio, FQ
Debt to Equity, FQ
Net Debt, FQ
Quick Ratio, FQ
Total Assets, FQ
Total Debt, FQ
Operating Metrics
Return on Assets, TTM
Return on Equity, TTM
Return on Invested Capital, TTM
Revenue per Employee, TTM
Price History
Average Volume (10 day)
Beta - 1 Year
Price - 52 Week High
Price - 52 Week Low
Dividends
Dividends Paid, FY
Dividends per Share, FY
Expected Annual Dividends
Dividends Yield
Margins
Net Margin, TTM
Gross Margin, TTM
Operating Margin, TTM
Pretax Margin, TTM
Income Statement
Basic EPS, Net Income
Earnings per Share, Basic, TTM
EBITDA, TTM
Gross Profit, FY
Last Annual EPS
Last Annual Revenue, FY
Net Income, FY
Total Revenue, FY
Free Cash Flow, TTM

Profile

Sector: Distribution Services
Industry: Medical Distributors
Gongwin Biopharm Holdings Co., Ltd. engages in the operation of Minimally Invasive Targeted Tumor Ablation business. It is a technology of minimally invasive treatment and can be directly applied to the treatment of various solid malignant tumors. Its products include PTS Minimally-Invasive Targeted Ablation and anti-tumor for canine used such as superficial malignant tumor in canine, malignant melanoma of the canine, lipoma of the canine and feline, and malignant bladder tumor of the canine and feline. The company was founded by John Wu and Rocky Shih on March 27, 2014 and is headquartered in Taipei, Taiwan.